What is the role of stem cell transplantation (SCT) in the treatment of relapsed Burkitt lymphoma/Burkitt-like lymphoma (BL/BLL)?

Updated: Dec 20, 2019
  • Author: Ali H Kanbar, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

A French group has reported improved survival rates in patients with relapsed aggressive NHL who were treated with high-dose chemotherapy plus autologous SCT. [67] The only significant prognostic factor noted was sensitivity to reinduction chemotherapy at the time of relapse. A 3-year survival rate of 36% in sensitive relapse (SR) versus 14% in resistant relapse (RR) was reported. [67] Subsequent studies have reported similar outcomes.

Patients with relapsed Burkitt lymphoma (BL) with chemosensitive disease should be considered for high-dose chemotherapy plus autologous SCT; alternative therapies should be considered for those with RR (see the Sweetenham et al reference [63] ).

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!